Seer, Inc.
NASDAQ:SEERBiotechnology
+$0.01 today
- Market cap
- $80.37M
- Beta
- 1.59
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$1.26
Volume 0.23M
Average 0.32M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Seer, Inc.
NASDAQ:SEER
Intrinsic Alpha fair value
Locked
Current Price
$1.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +3.2% | +24.1% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +3.2% over three years. Forward estimates point to Revenue at +24.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Kymera Therapeutics, Inc. NASDAQ:KYMR | $10.89B | $127.57 | Not rated | -28.3 | +86.87% |
Pharvaris N.V. NASDAQ:PHVS | $2.34B | $33.36 | Not rated | -11.0 | +28.57% |
Nurix Therapeutics, Inc. NASDAQ:NRIX | $1.69B | $15.48 | Undervalued | -6.4 | -1.61% |
Mineralys Therapeutics, Inc. NASDAQ:MLYS | $1.36B | $15.33 | Not rated | -13.9 | -67.28% |
ORIC Pharmaceuticals, Inc. NASDAQ:ORIC | $814.71M | $7.86 | Not rated | -6.7 | -33.36% |
Monte Rosa Therapeutics, Inc. NASDAQ:GLUE | $800.67M | $9.37 | Not rated | -9.1 | -35.86% |
Cullinan Therapeutics, Inc. NASDAQ:CGEM | $667.39M | $10.28 | Not rated | -4.0 | +6.63% |
Sana Biotechnology, Inc. NASDAQ:SANA | $605.26M | $2.02 | Not rated | -3.5 | -45.59% |
Shattuck Labs, Inc. NASDAQ:STTK | $473.57M | $4.65 | Not rated | -10.9 | +128.06% |
C4 Therapeutics, Inc. NASDAQ:CCCC | $362.43M | $2.76 | Not rated | -4.9 | -1.00% |
Lyell Immunopharma, Inc. NASDAQ:LYEL | $351.57M | $14.30 | Not rated | -1.1 | -19.34% |
PepGen Inc. NASDAQ:PEPG | $301.98M | $4.36 | Not rated | -1.6 | -30.74% |
Quantum-Si incorporated NASDAQ:QSI | $229.78M | $1.15 | Not rated | -2.1 | -16.41% |
AN2 Therapeutics, Inc. NASDAQ:ANTX | $172.64M | $4.55 | Not rated | -4.9 | +358.33% |
Foghorn Therapeutics Inc. NASDAQ:FHTX | $124.12M | $2.07 | Not rated | -3.8 | -63.17% |
Molecular Partners AG NASDAQ:MOLN | $112.71M | $2.94 | Not rated | -2.0 | -36.40% |
Nkarta, Inc. NASDAQ:NKTX | $85.23M | $1.19 | Not rated | -2.0 | -35.75% |
MediciNova, Inc. NASDAQ:MNOV | $68.66M | $1.40 | Not rated | -5.6 | -6.99% |
Continue the stock analysis
Jump to another research area for this company.